Oxycodone drug interactions
Pro Research Analysisby 
Searched over 200M research papers
Oxycodone Drug Interactions: A Comprehensive Overview
Introduction to Oxycodone Drug Interactions
Oxycodone, a potent opioid analgesic, is widely used for managing moderate to severe pain. However, its interactions with other drugs can significantly impact its efficacy and safety. Understanding these interactions is crucial for optimizing therapeutic outcomes and minimizing adverse effects.
Oxycodone and Benzodiazepines: Synergistic Effects
Pharmacokinetic and Pharmacodynamic Interactions
The combination of oxycodone and benzodiazepines, such as diazepam, has been extensively studied due to their potential for adverse drug interactions. Pharmacokinetic modeling suggests that at normal doses, diazepam does not significantly affect oxycodone metabolism. However, at very high doses, diazepam can inhibit oxycodone metabolism, leading to increased drug levels1. Pharmacodynamically, diazepam and oxycodone may compete for the same binding sites on opioid receptors, potentially enhancing each other's effects and increasing the risk of respiratory depression1 6.
Clinical Implications
The co-administration of oxycodone and benzodiazepines can potentiate respiratory depression, a critical concern highlighted by the FDA. This interaction underscores the importance of cautious dosing and monitoring when these drugs are prescribed together6.
Oxycodone and CYP Enzyme Inhibitors: Increased Drug Exposure
Role of CYP3A4 and CYP2D6
Oxycodone is primarily metabolized by the cytochrome P450 enzymes CYP3A4 and CYP2D6. Inhibition of these enzymes can lead to significant increases in oxycodone levels. For instance, the combination of paroxetine (a CYP2D6 inhibitor) and itraconazole (a CYP3A4 inhibitor) can increase oxycodone exposure by nearly threefold, enhancing its pharmacological effects and potential side effects7.
Clinical Considerations
When prescribing oxycodone alongside CYP3A4 and CYP2D6 inhibitors, healthcare providers must adjust dosages and closely monitor patients for signs of increased opioid effects, such as drowsiness and respiratory depression7.
Oxycodone and Adjuvant Analgesics: Blood-Brain Barrier Interactions
Transport and Efficacy
Certain adjuvant analgesics, including antidepressants and antiarrhythmics, can interact with oxycodone at the blood-brain barrier. Drugs like amitriptyline and mexiletine can inhibit the transport of oxycodone, potentially enhancing its central nervous system effects. However, these interactions are generally significant only at high concentrations, unlikely to be reached at therapeutic doses4.
Practical Implications
While these interactions may not be clinically significant at standard doses, they highlight the need for awareness of potential changes in oxycodone efficacy when combined with other analgesics4.
Oxycodone and Multiple Drug Combinations: Enhanced Toxicity
Evidence from Fatality Cases
Studies of drug abuse fatalities involving oxycodone reveal that the presence of multiple drugs can lower the mean blood concentration of oxycodone, suggesting enhanced toxicity. This finding indicates that oxycodone, when combined with other centrally acting drugs, is more toxic than when used alone2 5.
Safety Recommendations
In cases of polypharmacy, especially involving other CNS depressants, it is crucial to consider the cumulative effects and potential for increased toxicity. This approach is vital for accurately determining the cause of death in overdose cases and for guiding safe prescribing practices2 5.
Conclusion
Oxycodone's interactions with other drugs, particularly benzodiazepines, CYP enzyme inhibitors, and multiple CNS depressants, can significantly impact its pharmacokinetics and pharmacodynamics. These interactions necessitate careful consideration in clinical practice to ensure patient safety and effective pain management. By understanding and monitoring these interactions, healthcare providers can mitigate risks and optimize therapeutic outcomes for patients using oxycodone.
Sources and full results
Most relevant research papers on this topic
Drug-Drug Interaction Between Oxycodone and Diazepam by a Combined in Silico Pharmacokinetic and Pharmacodynamic Modeling Approach.
Pharmacodynamics plays a more significant role than pharmacokinetics in revealing the mechanism of drug-drug interactions between oxycodone and diazepam, with no significant interaction observed at normal doses.
Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions.
Oxycodone's toxicity is enhanced when combined with other centrally acting drugs, as shown by lower mean blood concentrations in multiple drug-induced deaths compared to single drug-induced deaths.
Observational Study
Highly CitedPhysiologically based pharmacokinetic modelling of oxycodone drug-drug interactions.
The PBPK model effectively simulates drug-drug interactions between oxycodone and its metabolites, providing a tool for forecasting interactions with other CYP3A4 and CYP2D6 inhibitors.
In Vitro StudyDrug-drug interaction between oxycodone and adjuvant analgesics in blood-brain barrier transport and antinociceptive effect.
Adjuvant analgesics may interact with oxycodone's blood-brain barrier transport at high concentrations, but significant interactions are unlikely at therapeutically or pharmacologically relevant concentrations.
In Vitro StudyOxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions.
Oxycodone's toxicity is enhanced when combined with other centrally acting drugs, as evidenced by lower mean blood concentrations in multiple-drug-induced deaths compared to single-drug-induced deaths.
Observational StudyA high-throughput bioanalytical assay to support pharmacokinetic interaction study of oxycodone and diazepam in Sprague Dawley rats
The developed LC-MS/MS assay effectively determines oxycodone and diazepam levels in rat plasma, aiding in understanding their pharmacokinetic and pharmacodynamic interactions.
Non-RCT
Animal StudyExposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.
Inhibiting CYP2D6 and CYP3A4 pathways together increases oral oxycodone exposure, but CYP2D6 inhibition alone has minimal clinical importance.
RCTHighly CitedUpdated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone
Oxycodone pharmacokinetics have significantly improved over the last decade, with data on special populations, drug interactions, and abuse-deterrent formulations.
Literature ReviewHighly CitedContribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration
Oxycodone itself is responsible for the analgesic effect, with its metabolites having minimal analgesic effect due to low concentrations at the site of action.
Systematic Review